FLOW Trial Sub-study shows Semaglutide may reduces kidney and cardiovascular risks, regardless of MRA use
Time to read: 02:33. At the recent European Association for the Study of Diabetes (EASD) Annual Meeting, Dr Peter Rossing, from the Steno Diabetes Center Copenhagen, presented the findings from a key subanalysis of the landmark FLOW trial, shedding light on the impact of semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD).
